Christopher M. Coleman

Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

Julie Dyall, Christopher M. Coleman, Brit J. Hart et al. · Antimicrobial Agents and Chemotherapy · 2014 · 695 citations · Full text

Dopamine Receptor, Viral Diagnostics, Emerging Infectious Diseases +14

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

Rachael A Evans, Hamish McAuley, Ewen M. Harrison et al. · The Lancet Respiratory Medicine · 2021 · 636 citations · Full text

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

Rachael A Evans, Olivia C. Leavy, Matthew Richardson et al. · The Lancet Respiratory Medicine · 2022 · 407 citations · Full text

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

Kirsten Kulcsar, Christopher M. Coleman, Sarah E. Beck et al. · JCI Insight · 2019 · 381 citations · Full text

Saudi Arabia, Diabetic Mice, Immunology +19

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

Christopher M. Coleman, Ye V. Liu, Haiyan Mu et al. · Vaccine · 2014 · 303 citations · Full text

Vaccination, Cross-protection, Immunology +6